On March 12, 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, reported that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA (Press release, Renovorx, MAR 12, 2024, View Source [SID1234641085]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mr. Bagai will meet with investors and participate in a fireside chat hosted by Jonathan Aschoff, Senior Research Analyst at Roth MKM on Tuesday, March 19, 2024 at 10:00 am PT.
Mr. Bagai will discuss recent Company milestones, including an initial positive interim analysis on the Company’s pivotal Phase III TIGeR-PaC clinical trial. The study is evaluating the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of locally advanced pancreatic cancer.
He will also discuss other significant milestones achieved and the Company’s plans for 2024 and beyond, including recent completion of a $6.1 million private placement that has extended cash runway, allowing the Company to drive towards its key goal of a second interim analysis for TIGeR-PaC that will be triggered by the 52nd event (death), which is estimated to occur in late 2024.
ROTH MKM Healthcare Opportunities Conference
Date: March 19, 2024
Time: 10:00 AM PT
Speaker: Shaun Bagai, CEO
Location: The Ritz Carlton, Dana Point, CA
Webcast: Registration Link
To schedule a one-on-one investor meeting with RenovoRx’s management team, please contact your ROTH MKM representative or KCSA Strategic Communications at [email protected].